BVT-0196-C100100 µgCHF 30.00
BVT-0196-C500500 µgCHF 50.00
BVT-0196-M0011 mgCHF 75.00
BVT-0196-M0055 mgCHF 160.00
|Synonyms||NSC122750; BRN1633093; U-29135|
|Source/Host Chemicals||Isolated from Streptomyces hygroscopicus.|
|Purity Chemicals||≥98% (HPLC)|
|Solubility||Soluble in methanol or DMSO; insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light when in solution.|
Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
|Product Specification Sheet|
- Potent antitumor compound.
- pp60src tyrosine kinase inhibitor.
- Inhibits c-mycgene expression in murine lymphoblastoma cells.
- Inhibits the transforming activity of abl, erbB, fps, src and yes.
- Binds specifically to heat shock protein 90 (HSP90) and to its endoplasmic reticulum homolog GP96 (GRP94).
- Destabilizes several oncogene and proto-oncogene products.
- Potent nuclear hormone receptor family inhibitor.
- Geldanamycin, a new antibiotic: C. DeBoer, et al.; J. Antibiot. 23, 442 (1970)
- Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group: H. Yamaki, et al.; J. Antibiot. 42, 604 (1989)
- Geldanamycin selectively destabilizes and conformationally alters mutated p53: M.V. Blagosklonny, et al.; Oncogene 11, 933 (1995)
- Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives: R.C. Schnur, et al.; J. Med. Chem. 38, 3806 (1995)
- Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells: L. Whitesell & P. Cook; Mol. Endocrinol. 10, 705 (1996)
- Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity: L. Neckers, et al.; Invest. New Drugs 17, 361 (1999), (Review)
- Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs: M.V. Blagosklonny; Leukemia 16, 455 (2002), (Review)
- Geldanamycin enhances hepatocyte growth factor stimulation of eNOS phosphorylation in endothelial cells: K. Makondo, et al.; Eur. J. Pharmacol. 582, 110 (2007)
- HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo: E. Lesko, et al.; Anticancer Drugs 18, 1173 (2007)
- Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo: S.A. Lang, et al.; Mol. Cancer Ther. 6, 1123 (2007)
- Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells: F. Koga, et al.; Cell Cycle 6, 1393 (2007)
- Hsp90-inhibitor geldanamycin abrogates G(2) arrest in p53-negative leukemia cell lines through the depletion of Chk1: K. Sugimoto, et al.; Oncogene 27, 3091 (2008)